Latest Healthcare News

Artrya Limited has begun generating fee-per-scan revenues from its Salix Coronary Plaque module at Tanner Health in the U.S., marking a key commercial milestone for the AI-powered cardiac imaging platform.

Vita Life Sciences forecasts solid sales and profit growth for FY2025, driven by strong performances in Malaysia and Singapore, while cautiously managing challenges in China exports.

Acrux Limited has sold the US registration and distribution rights for its Prilocaine 2.5% and Lidocaine 2.5% cream for US$550,000, redirecting resources towards its growing Hormone Replacement Therapy portfolio.

Rhythm Biosciences has begun commercialising ColoSTAT®, its blood-based colorectal cancer diagnostic test, following an updated ISO15189, 2022 accreditation. The test offers a new option for symptomatic patients where stool-based screening is unsuitable.

EBR Systems has completed the first patient implant in its Totally Leadless CRT (TLC-AU) feasibility study, marking a strategic step toward expanding wireless cardiac resynchronisation therapy for heart failure patients.

EBR Systems has expanded its intellectual property holdings with four new patents, reinforcing its lead in wireless cardiac pacing technology, while facing a preliminary setback on a patent term extension application.

Argenica Therapeutics’ AI-powered reanalysis of its Phase 2 trial reveals significant efficacy of ARG-007 in severe acute ischemic stroke patients, highlighting improved functional outcomes and reduced brain damage.

Emyria Limited is scaling up its Perth Empax clinic with increased therapist approvals and treatment rooms, setting the stage for broader national clinical growth next year.

Fisher & Paykel Healthcare has updated its dividend announcement to include the Australian Dollar equivalent, providing clearer insight for investors ahead of the mid-December payment.

Tissue Repair Limited has responded to an ASX price query following a sharp rise in its share price and trading volume, denying any undisclosed information and confirming compliance with listing rules.

InhaleRx advances its clinical pipeline with a new oral treatment for resistant depression and plans a strategic rebrand to Nexalis Therapeutics, signaling a broader focus beyond inhaled therapies.

Mayne Pharma has rejected Cosette Pharmaceuticals’ notice to terminate their merger agreement, citing Cosette’s failure to meet obligations that led to regulatory approval issues. The dispute raises fresh uncertainty over the proposed acquisition’s future.